ECSP099304A - Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación - Google Patents

Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación

Info

Publication number
ECSP099304A
ECSP099304A EC2009009304A ECSP099304A ECSP099304A EC SP099304 A ECSP099304 A EC SP099304A EC 2009009304 A EC2009009304 A EC 2009009304A EC SP099304 A ECSP099304 A EC SP099304A EC SP099304 A ECSP099304 A EC SP099304A
Authority
EC
Ecuador
Prior art keywords
marked
glutamic acid
derivatives
glutamine
procedures
Prior art date
Application number
EC2009009304A
Other languages
English (en)
Inventor
Matthias Friebe
Heribert Schmitt-Willich
Lutz Lehmann
Keith Graham
Ludger Dinkelborg
Raisa Nikolaevna Krasikowa
Yuri Belokon
Olga Fedorovna Kuznetsova
Mathias Berndt
Original Assignee
Bayer Schering Pharma Ag
A N Nesmeyanov Inst Ineos Ras
Inst Of The Human Brain Russia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2006138584/04A external-priority patent/RU2395489C2/ru
Priority claimed from EP06090211A external-priority patent/EP1923382A1/de
Application filed by Bayer Schering Pharma Ag, A N Nesmeyanov Inst Ineos Ras, Inst Of The Human Brain Russia filed Critical Bayer Schering Pharma Ag
Publication of ECSP099304A publication Critical patent/ECSP099304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04—Nickel compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04—Nickel compounds
    • C07F15/045—Nickel compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen los compuestos y la síntesis de ácido L-glutámico marcado con [F-18], L-glutamato marcado con [F-18], sus derivados de acuerdo con la fórmula (I) y sus usos
EC2009009304A 2006-11-01 2009-04-30 Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación ECSP099304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006138584/04A RU2395489C2 (ru) 2006-11-01 2006-11-01 [f-18] меченная l-глютаминовая кислота, [f-18] меченный l-глютамин, их производные и их применение, а также способ их получения
EP06090211A EP1923382A1 (de) 2006-11-18 2006-11-18 [F-18] markierte L-Glutaminsäure, [F-18] markiertes Glutamin, ihre Derivate und ihre Verwendung sowie Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ECSP099304A true ECSP099304A (es) 2009-07-31

Family

ID=38896929

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009304A ECSP099304A (es) 2006-11-01 2009-04-30 Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación

Country Status (23)

Country Link
US (2) US20100217011A1 (es)
EP (1) EP2086924B1 (es)
JP (4) JP5529540B2 (es)
KR (1) KR101495924B1 (es)
CN (1) CN101595083B (es)
AR (1) AR071043A1 (es)
AU (1) AU2007315203B2 (es)
BR (1) BRPI0718055A2 (es)
CA (1) CA2667395C (es)
CL (2) CL2007003169A1 (es)
CO (1) CO6180453A2 (es)
CU (1) CU23825B1 (es)
EA (1) EA017713B1 (es)
EC (1) ECSP099304A (es)
ES (1) ES2701423T3 (es)
IL (1) IL198022A0 (es)
MX (1) MX2009004686A (es)
NO (1) NO20092123L (es)
NZ (1) NZ576582A (es)
PE (1) PE20091723A1 (es)
SV (1) SV2009003251A (es)
TW (1) TWI415626B (es)
WO (1) WO2008052788A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123621A1 (de) * 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Neue {F-18}-markierte L-Glutaminsäure- und L-Glutaminderivate (I), ihre Verwendung sowie Verfahren zu ihrer Herstellung
NZ576582A (en) 2006-11-01 2011-12-22 Bayer Schering Pharma Ag [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation
EP2123620A1 (en) * 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
EP2123619A1 (de) * 2008-05-20 2009-11-25 Bayer Schering Pharma AG Neue [F-18]-Markierte L-Glutaminsäure-und L-Glutaminderivate (II), ihre Verwendung sowie Verfahren zu ihrer Herstellung
CA2736861C (en) 2008-10-10 2017-11-14 Roger Schibli 18f-labelled folates as pet radiotracers
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
CN102595888A (zh) * 2009-08-14 2012-07-18 宾夕法尼亚大学理事会 4-氟谷氨酰胺的单一非对映异构体及其制备方法和应用
EP2322171A3 (en) * 2009-11-17 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Fluorine labeled L-glutamic acid derivatives
CN102711841A (zh) * 2009-11-17 2012-10-03 拜耳医药股份有限公司 碘标记的高谷氨酸和谷氨酸衍生物
CA2780930A1 (en) 2009-11-17 2011-05-26 Mathias Berndt Method for production of f-18 labeled glutamic acid derivatives
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
US9139316B2 (en) 2010-12-29 2015-09-22 Cardinal Health 414, Llc Closed vial fill system for aseptic dispensing
EP2520557A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Novel precursors of glutamate derivatives
EP2520556A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Radiolabeled amino acids for diagnostic imaging
WO2013012813A1 (en) 2011-07-15 2013-01-24 Cardinal Health 414, Llc Modular cassette synthesis unit
WO2013012822A1 (en) 2011-07-15 2013-01-24 Cardinal Health 414, Llc Systems, methods, and devices for producing, manufacturing, and control of radiopharmaceuticals
US9417332B2 (en) 2011-07-15 2016-08-16 Cardinal Health 414, Llc Radiopharmaceutical CZT sensor and apparatus
US20130022525A1 (en) * 2011-07-15 2013-01-24 Cardinal Health 414, Llc Methods and compositions for drying in the preparation of radiopharmaceuticals
WO2020010228A1 (en) * 2018-07-06 2020-01-09 The Regents Of The University Of California Deconstructive functionalization methods and compounds
CN109369445B (zh) * 2018-11-20 2021-10-15 首都医科大学 用于诊断和治疗的放射性谷氨酰胺衍生物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1461184A (fr) * 1964-12-23 1966-01-07 Takeda Chemical Industries Ltd Procédé de préparation d'isoxazolidones substituées en position 5
DE1620522A1 (de) * 1964-12-23 1970-04-23 Takeda Chemical Industries Ltd Verfahren zur Herstellung von 5-substituierten Isoxazolidonverbindungen
US5264570A (en) * 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
US5267570A (en) * 1992-12-30 1993-12-07 Preston Myra S Method of diagnosing and treating chronic fatigue syndrome
GB9324872D0 (en) 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
US6459003B1 (en) * 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
AU2001278945A1 (en) 2000-08-10 2002-02-25 Eli Lilly And Company 4-substituted d-glutamic acid derivatives for use as antibiotic
AU2001288658A1 (en) 2000-09-01 2002-03-13 Annovis, Inc. Screen for glutamate reuptake inhibitors, stimulators, and modulators
DE10223451A1 (de) * 2002-05-25 2003-12-24 Abx Gmbh Verfahren zur Herstellung von 18F-fluorierten alpha-Aminosäuren
CN100581589C (zh) * 2002-08-02 2010-01-20 马林克罗特公司 放射标记的氨基酸类似物,其制备物及用途
DE10346228B4 (de) * 2003-09-25 2009-04-09 Eberhard-Karls-Universität Tübingen Universitätsklinikum Herstellung von [18F]fluormarkierten aromatischen L-Aminosäuren
US7270799B2 (en) * 2004-01-15 2007-09-18 Nst Neurosurvival Technologies Ltd. Perturbed membrane-binding compounds and methods of using the same
US7483732B2 (en) 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
US20070011016A1 (en) * 2005-07-07 2007-01-11 Alderman Joseph B Springing interests flowing from benefits that run with land
EP2123621A1 (de) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Neue {F-18}-markierte L-Glutaminsäure- und L-Glutaminderivate (I), ihre Verwendung sowie Verfahren zu ihrer Herstellung
EP1923382A1 (de) 2006-11-18 2008-05-21 Bayer Schering Pharma Aktiengesellschaft [F-18] markierte L-Glutaminsäure, [F-18] markiertes Glutamin, ihre Derivate und ihre Verwendung sowie Verfahren zu ihrer Herstellung
NZ576582A (en) 2006-11-01 2011-12-22 Bayer Schering Pharma Ag [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation
EP2123619A1 (de) * 2008-05-20 2009-11-25 Bayer Schering Pharma AG Neue [F-18]-Markierte L-Glutaminsäure-und L-Glutaminderivate (II), ihre Verwendung sowie Verfahren zu ihrer Herstellung
EP2123620A1 (en) * 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them

Also Published As

Publication number Publication date
JP5749836B2 (ja) 2015-07-15
CN101595083A (zh) 2009-12-02
US20140301948A1 (en) 2014-10-09
EP2086924B1 (de) 2018-09-12
CL2007003169A1 (es) 2008-07-04
JP2014221764A (ja) 2014-11-27
CL2012000768A1 (es) 2012-09-14
JP2014062113A (ja) 2014-04-10
MX2009004686A (es) 2009-09-28
AU2007315203A1 (en) 2008-05-08
ES2701423T3 (es) 2019-02-22
JP2014088389A (ja) 2014-05-15
JP2010508317A (ja) 2010-03-18
TWI415626B (zh) 2013-11-21
EA017713B1 (ru) 2013-02-28
CA2667395A1 (en) 2008-05-08
WO2008052788A1 (de) 2008-05-08
EP2086924A1 (de) 2009-08-12
CA2667395C (en) 2016-05-10
BRPI0718055A2 (pt) 2013-11-05
US20100217011A1 (en) 2010-08-26
TW200920407A (en) 2009-05-16
AR071043A1 (es) 2010-05-26
CU20090072A7 (es) 2011-09-21
PE20091723A1 (es) 2009-12-11
JP5529540B2 (ja) 2014-06-25
NO20092123L (no) 2009-07-30
CU23825B1 (es) 2012-06-21
KR20090096597A (ko) 2009-09-11
NZ576582A (en) 2011-12-22
US9375497B2 (en) 2016-06-28
JP5815651B2 (ja) 2015-11-17
AU2007315203B2 (en) 2013-06-27
EA200970428A1 (ru) 2009-12-30
KR101495924B1 (ko) 2015-02-25
HK1138568A1 (en) 2010-08-27
SV2009003251A (es) 2009-12-15
CN101595083B (zh) 2014-12-10
CO6180453A2 (es) 2010-07-19
IL198022A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CU20090072A7 (es) Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación
PA8827401A1 (es) Nuevos derivados de ácido l-glutámico y l-glutamina marcados con [f-18] (i), su uso y procedimiento para su preparación
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
ECSP077271A (es) Derivados de pirimidina
PA8791801A1 (es) Compuestos de pirazol
CR11623A (es) Compuestos
ECSP077259A (es) Derivados de pirimidina
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
AR075892A1 (es) Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
ECSP099565A (es) Compuesto de 2-amino pirimidina
ECSP12011651A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
DOP2010000155A (es) Derivados de pirazol como inhibidores de 5-lo
UY31836A (es) Nuevo ácido l-glurámico marcado con [f-18] y derivados de l-glutamina marcada con [f-18] (ii), su uso y procedimientos para su preparación
ECSP099679A (es) Nuevos compuestos y sus usos 707
SV2007002315A (es) Derivados de octahidropirrolo[3,4-c]pirrol ref. pc32623a
ECSP088933A (es) Métodos para preparar derivados de ácido glutámico y sus intermedios
DOP2009000098A (es) Ácido l-glutamico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación
UY30683A1 (es) Acido l-glutamico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, asi como procedimientos para su preparacion.
GT200600153A (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.